Carmelo Carlo-Stella

Associate Professor Hematology MED/15

Associate Professor of Hematology, Humanitas University

Director, Postgraduate School of Hematology, Humanitas University

Section Chief, Lymphoid Malignancies and Cancer Therapeutics, Humanitas Clinical and Research Center – IRCCS

Teaching appointment, System Diseases 2 – Blood Diseases, Humanitas University Medical School

E-mail carmelo.carlostella@hunimed.eu

Phone +39 02 8224 4577

Web site https://www.humanitas.it/medici/carmelo-carlostella

Biosketch

I received my education at the University of Pavia, where I obtained the M.D. degree cum Laude (1981) and the specialization in Internal Medicine (1986).

In 1993, I received the specialization in Hematology at the University of Parma.

From December 1999 to June 2011, I was a member of the active staff in Onco-Hematology at the Fondazione IRCCS Istituto Nazionale Tumori in Milano, where I also served (2005 to 2011) as Director of the Hematopoietic Stem Cell Manipulation Unit.

From 2006 to 2016, I served as Associate Professor of Medical Oncology at the University of Milano.

In 2011, I moved to the Humanitas Clinical and Research Center, where I currently am Section Chief of Lymphoid Malignancies and Cancer Therapeutics.

In January 2017, I was appointed as Associate Professor of Hematology at Humanitas University.

Scientific and Research Interests

Translational Research 

My activity is focused explicitly on translational research aimed at: (i) early phase preclinical and clinical development of molecularly targeted agents or monoclonal antibodies (naked, drug-conjugated, bispecific) for the treatment of relapsed/refractory lymphoma; (ii) pharmacological targeting of tumor microenvironment in lymphoma; (iii) optimizing the clinical management of lymphoma patients using the liquid biopsy and circulating tumor DNA.

Clinical Research

I am the principal investigator or co-investigator of phase 1 and 2 clinical trials aimed at the development of novel anti-cancer immunotherapy in relapsed/refractory Hodgkin and non-Hodgkin lymphoma.

As of Oct 30, 2019, scientific publications include 245 peer-reviewed articles in journals covered by the JCR®. H-index (Google Scholar) is equal to 42.

Selected Publications

  1. Reichel J., Chadburn A., Rubinstein P.G., Giulino-Roth L., Tam W., Liu Y., Gaiolla R., Eng K., Brody J., Inghirami G., Carlo-Stella C., Santoro A., Rahal D., Totonchy J., Elemento O., Cesarman E., Roshal M.: Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125:1061-1072, 2015
  2. Santoro A., Mazza R., Pulsoni A., Re A., Bonfichi M., Zilioli V.R., Salvi F., Merli F., Anastasia A., Luminari S., Annechini G., Gotti M., Peli A., Liberati A.M., Di Renzo N., Castagna L., Giordano L., Carlo-Stella C.: Bendamustine in combination with Gemcitabine and Vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 34:3293-9, 2016
  3. Merryman R.W., Kim H.T., Zinzani P.L., Carlo-Stella C., Ansell S.M., Perales M.A., Avigdor A., Halwani A.S., Houot R., Marchand T., Dhedin N., Lescaut W., Thiebaut-Bertrand A., François S., Stamatoullas-Bastard A., Rohrlich P-S, Labussière Wallet H., Castagna L., Santoro A., Bachanova V., Bresler S.C., Srivastava A., Kim H., Pesek E., Chammas M., Reynolds C., Ho V.T., Antin J.H., Ritz J., Soiffer R.J., Armand P.: Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after PD-1 Blockade in Relapsed/Refractory Lymphoma. Blood 129:1380-1388, 2017.
  4. Spina V., Bruscaggin A., Cuccaro A., Martini M., Di Trani M., Forestieri G., Manzoni M., Condoluci A., Arribas A., Terzi-Di-Bergamo L., Locatelli S.L., Cupelli E., Ceriani L., Moccia A.A., Stathis A., Nassi L., Deambrogi C., Diop F., Guidetti F., Cocomazzi A., Annunziata S., Rufini V., Giordano A., Neri A., Boldorini R., Gerber B., Bertoni F., Ghielmini M., Stüssi G., Santoro A., Cavalli F., Zucca E., Larocca L.M., Gaidano G., Hohaus S., Carlo-Stella C., Rossi D: Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. Blood 131:2413-2415, 2018
  5. Locatelli S.L., Careddu G., Serio S., Consonni F.M., Maeda A., Viswanadha S., Vakkalanka S., Castagna L., Santoro A., Allavena P., Sica A., Carlo-Stella C.: Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530. Clin Cancer Res. 25:1098-1112, 2019.
Why
Humanitas
University?
An Established Institution

An Established Institution
Humanitas is a renowned healthcare institution that has offered Medical Degrees for well over a decade as a partner of the University of Milan.

An International Career

An International Career
Join our international medical community where classes are taught in English by experienced professors and medical doctors from around the world. Your degree will allow you to work as a MD in the EU and abroad.

Clinical Experience

Clinical Experience
Direct clinical experience is supported by a solid tutoring system and starts in your third year, which gives you considerable practical experience.

Innovative and Active Teaching

Innovative and Active Teaching
Humanitas curriculum is enhanced by a wide variety of active learning methods based on a student-centred approach (Problem-Based Learning, Case method, Concept maps, Simulated patients).

Milano and Italy

Milano and Italy
Enjoy the style, culture, gastronomy and entertainment of one of Europe's most exciting cities. Venture further to experience the delights of Italy or use the opportunity to learn Italian.

Advanced Research and Technology

Advanced Research and Technology
Humanitas can count on state-of-the-art technologies and research experience. The Campus includes also a simulation centre of 1000 sm, designed according to the highest technological standards.

Contact Us

Contact
Humanitas University
Via Rita Levi Montalcini 4,
Pieve Emanuele 20090 Milan, Italy

To receive our updates subscribe here: Newsletter.

How to Reach Us
From Malpensa Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Linate Airport

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From Central station

Take the A8 highway, following the signs for Milan. Get on the Tangenziale Ovest (western ring road), exit at Quinto de’ Stampi/Via dei Missaglia (7 bis). Follow the route described in the highway section.

From the city center

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

From the highway

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.

By public transport

Go straight on from Porta Ticinese, to Corso San Gottardo, to via Meda, via Montegani, and via dei Missaglia, then follow the signs for Istituto Clinico Humanitas, or Basiglio Milano 3.